Mark Kudolo

First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer

Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-<i>b</i>]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities

Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor

Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity

Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells

Selective targeting of the αC and DFG-out pocket in p38 MAPK

Discovery and Evaluation of Enantiopure 9H-pyrimido[4,5-b]indoles as Nanomolar GSK-3β Inhibitors with Improved Metabolic Stability

Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors

Pyridinylimidazoles as GSK3β Inhibitors: The Impact of Tautomerism on Compound Activity via Water Networks

Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen Synthase Kinase-3β Inhibitors

Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen synthase kinase-3β inhibitors

Pyridinylimidazoles as GSK3β inhibitors: the impact of tautomerism on compound activity via water networks

Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen synthase kinase-3β inhibitors

Design, Synthesis and Biological Evaluation of 7 Chloro-9H-pyrimido[4,5-b]indole-based Glycogen synthase kinase-3β inhibitors

Pyridinylimidazoles as GSK3β inhibitors: the impact of tautomerism on compound activity via water networks

Pyridinylimidazoles as GSK3β inhibitors: the impact of tautomerism on compound activity via water networks

Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3